<DOC>
	<DOC>NCT01715805</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD</brief_summary>
	<brief_title>An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Patients who have provided consent prior to any specific procedure Meet the The Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSMIVTR) criteria for Major Depressive Disorder (MDD) Have a minimum score of 20 on 17Item Hamilton Depression (HAMD17) rating scale at Visits 1 and 2 Patients who do not meet DSMIVTR criteria for MDD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>MDD</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>